Yes, in deed. For all the prongs in the fire, AMBS is still valued like a red headed step child. That should tell you all you need to know right now about how the company is perceived in the market place. Lympro is the first bullet for AMBS to fire and we'll see how that penetrates the market if and when Lympro gets it day in the sun. But so far, the market doesn't give a rat's ass about anything AMBS is doing. Hopefully it will by year's end.